Results: AV block was asymptomatic in 119 (84.4%) and complete in 100 (70.9%) patients. Incomplete AV block progressed to complete in 29 (70.7%) patients with incomplete block over 2.8±3.4 years (1-155 months). Narrow QRS complex was present in 18 of 26 patients (69.2%) with congenital, and 106 of 115 (92.2%) with childhood AV block. Pacemakers were implanted in 112 children (79.4%), during the first year of life in 18 (16.1%) and before 10 years of age in 90 (80.4%). The mean delay between diagnosis of AVB and pacemaker implants was 2.6±3.9 years (0-300 months). The pacing indication was prophylactic in 70 children (62.5%). During a median follow-up of 11.6±6.7 years (1-32 years), no patient died or developed dilated cardiomyopathy. The long-term follow-up was uncomplicated in 127 children (90.1%).
Cardiac progenitors issued from human embryonic stem cells: a novel therapeutic agent in right ventricular dysfunction secondary to congenital heart diseases?
Virginie Lambert [Orateur] (1), André Capderou (2), Elodie Gouadon (2), Michel Pucéat (3), Catherine Rücker-Martin (2), Bertrand Stos (1), Benoît Decante (4), Nawel Bensari (1), Mohamed Ly (1), Emmanuel Lebret (1) Right ventricular (RV) failure is a major long-term complication of congenital heart disease, leading to morbidity and mortality. Since conventional therapy gives poor results, cell therapy may be a therapeutic option for cardiac repair. The ability of embryonic stem cells (ESC) differentiation towards a cardiomyogenic phenotype makes them attractive candidates. Our aim was to evaluate, in a large animal model, the effects of cardiac-committed human ESC transplantation on the RV function.
A model of RV dysfunction was created in 8 piglets using a surgical procedure mimicking RV tract sequellae of repaired tetralogy of Fallot leading, after 4 months, to a chronic combined RV overload. Four pigs received vehicle and 4 others received HUES-24 derived human cardiac progenitors cells injected at multiple sites into the free wall of RV myocardium. All pigs were immunosuppressed using tacrolimus. Myocardial function was measured 3 months after cell transplantation by conductance catheter technique using maximal elastance (E max ) slope and ventricular energetics (stroke work, pression-volume area). The risk of ventricular arrhythmia was evaluated by programmed ventricular stimulation at the end of the follow-up. Structural remodelling was assessed by histological examination.
All pigs survived and no complication occurred related to either myocardial injections or immunosuppression. No ventricular arrhythmia was induced. In all treated pigs, myocardial contractility was improved as assessed by an increasing E max slope relative to controls at the follow-up end (0.58±0.03 vs 0.40±0.08, p<0.05) whereas stroke work was similar in both groups. Improvement of contractility in treated pigs occurred without increasing of pressure-volume area suggesting that the myocardium is more efficient. In treated pigs, myocardial fibrosis appeared peritrabecular whereas, in controls, it was found in peritrabecular and perimyocyte areas.
Cell therapy by multiple trans-epicardial injections of ESC derived human cardiac progenitor cells in failed RV is feasible, improves RV myocardial contractility and allows a better adaptation to chronic overload. Introduction: Congenital long QT syndrome (LQTS) is a frequent cause of sudden cardiac death in children without structural heart disease. Given the recent progress in molecular diagnosis, a growing portion of LQTS patients is genetically affected but still asymptomatic. Their clinical outcome has not been clearly evaluated, and their optimal treatment is still discussed.
Methods:
Our database was searched for all patients with genotyped LQTS, identified by familial screening and aged 16 or less at diagnosis. We retrospectively recorded demographic and electrocardiographic data, personal and family histories and genetic diagnoses.
Results: 90 non proband children with genetically confirmed LQTS were included. Mean age at diagnosis was 7,3±5,2 years, and mean follow-up duration was 4,6±4,3 years. 7 (7,8%) were symptomatic before diagnosis, and 4 (4,4%) experienced LQTS-related symptoms during follow-up. No sudden cardiac death was reported. One LQT1 patient presented aborted cardiac arrest while swimming. Beta-blocker therapy was initiated in 51 patients (56,7%). Device therapy was infrequently used (one pacemaker, no implantable cardioverter defibrillator). Corrected QT interval (QTc) was the only factor correlated to the risk of LQTS-related symptom (p=0,02). Initiation of betablocker therapy was associated with mutations in KCNQ1 or KCNH2 (p<0,01), family history of LQTS-related cardiac event in a first-degree relative (p=0,02), diagnosis before four months of age (p=0,01) and a longer QTc (p=0,0016).
Conclusion:
Clinical outcome is favorable in genetically confirmed non proband LQTS children, and similar to what has been previously described despite less frequent use of beta blocker and device therapies. Thus, beta blocker therapy should probably not be initiated systematically in such patients, especially when QTc duration does not exceed 460 ms. ICD implantation does not seem mandatory in non proband LQT3 children, at least in their first years of life.
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